Dyne Therapeutics, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Dyne Therapeutics, Inc. (DYN) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $14.98 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-07-29
- Dyne Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $14.98M, a 42.32% increase year-over-year.
- Dyne Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $13.08M, a 0.47% increase year-over-year.
- Dyne Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $11.08M, a 26.72% increase year-over-year.
- Dyne Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $10.52M, a 56.22% increase year-over-year.
- Dyne Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $45.85M, a 0.03% decline from fiscal 2024.
- Dyne Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $45.86M, a 129.64% increase from fiscal 2023.
- Dyne Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $19.97M, a 31.59% increase from fiscal 2022.
- Dyne Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $15.18M, a 13.48% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.98M 10-Q · filed 2026-07-29 | $28.06M derived: sum of 2 quarters · filed 2026-07-29 | ||
| 2026-03-31 | $13.08M 10-Q · filed 2026-07-29 | |||
| 2025-12-31 | $45.85M 10-K · filed 2026-03-02 | |||
| 2025-09-30 | $11.08M 10-Q · filed 2025-11-05 | $21.61M derived: sum of 2 quarters · filed 2026-07-29 | $34.63M derived: sum of 3 quarters · filed 2026-07-29 | |
| 2025-06-30 | $10.52M 10-Q · filed 2026-07-29 | $23.54M derived: sum of 2 quarters · filed 2026-07-29 | ||
| 2025-03-31 | $13.02M 10-Q · filed 2026-07-29 | |||
| 2024-12-31 | $45.86M 10-K · filed 2026-03-02 | |||
| 2024-09-30 | $8.74M 10-Q · filed 2025-11-05 | $15.48M derived: sum of 2 quarters · filed 2025-11-05 | $35.39M derived: sum of 3 quarters · filed 2025-11-05 | |
| 2024-06-30 | $6.74M 10-Q · filed 2025-11-05 | $26.64M derived: sum of 2 quarters · filed 2025-11-05 | ||
| 2024-03-31 | $19.91M 10-Q · filed 2025-11-05 | |||
| 2023-12-31 | $19.97M 10-K · filed 2026-03-02 | |||
| 2023-09-30 | $4.88M 10-Q · filed 2024-11-12 | $9.62M derived: sum of 2 quarters · filed 2024-11-12 | $14.24M derived: sum of 3 quarters · filed 2024-11-12 | |
| 2023-06-30 | $4.75M 10-Q · filed 2024-11-12 | $9.37M derived: sum of 2 quarters · filed 2024-11-12 | ||
| 2023-03-31 | $4.62M 10-Q · filed 2024-11-12 | |||
| 2022-12-31 | $15.18M 10-K · filed 2025-02-27 | |||
| 2022-09-30 | $3.83M 10-Q · filed 2023-10-30 | $6.86M derived: sum of 2 quarters · filed 2023-10-30 | $11.35M derived: sum of 3 quarters · filed 2023-10-30 | |
| 2022-06-30 | $3.03M 10-Q · filed 2023-10-30 | $7.52M derived: sum of 2 quarters · filed 2023-10-30 | ||
| 2022-03-31 | $4.49M 10-Q · filed 2023-10-30 | |||
| 2021-12-31 | $17.54M 10-K · filed 2023-03-02 | |||
| 2021-09-30 | $3.64M 10-Q · filed 2022-11-03 | $7.88M derived: sum of 2 quarters · filed 2022-11-03 | $11.53M derived: sum of 3 quarters · filed 2022-11-03 | |
| 2021-06-30 | $4.24M 10-Q · filed 2022-11-03 | $7.89M derived: sum of 2 quarters · filed 2022-11-03 | ||
| 2021-03-31 | $3.65M 10-Q · filed 2022-11-03 | |||
| 2020-12-31 | $6.59M 10-K · filed 2022-03-10 | |||
| 2020-09-30 | $2.23M 10-Q · filed 2021-11-04 | $2.31M derived: sum of 2 quarters · filed 2021-11-04 | $2.38M derived: sum of 3 quarters · filed 2021-11-04 | |
| 2020-06-30 | $75.00K 10-Q · filed 2021-11-04 | $141.00K derived: sum of 2 quarters · filed 2021-11-04 | ||
| 2020-03-31 | $66.00K 10-Q · filed 2021-11-04 | |||
| 2019-12-31 | $26.00K 10-K · filed 2021-03-04 | |||
| 2019-09-30 | $7.00K 10-Q · filed 2020-11-05 | $11.00K derived: sum of 2 quarters · filed 2020-11-05 | $13.00K derived: sum of 3 quarters · filed 2020-11-05 | |
| 2019-06-30 | $4.00K 10-Q · filed 2020-11-05 | $6.00K derived: sum of 2 quarters · filed 2020-11-05 | ||
| 2019-03-31 | $2.00K 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |